Welcome to our dedicated page for Integrated Biopharma SEC filings (Ticker: INBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integrated BioPharma, Inc. filings document formal disclosures for a Delaware operating company whose public reports are tied to vitamins, nutritional supplements, herbal products and contract manufacturing. Recent Form 8-K filings furnish quarterly and fiscal-year results under Item 2.02, including press-release exhibits covering revenue, operating results and per-share data.
The filing record also includes material-event reports on credit-line arrangements and related-party lease matters involving the wholly owned subsidiary Manhattan Drug Company, as well as definitive proxy materials and annual meeting voting results covering director elections, executive-compensation votes, stockholder voting matters and governance procedures. Cover-page disclosures identify no securities registered on a national exchange under Section 12(b).
INTEGRATED BIOPHARMA INC director William H. Milmoe reported bona fide gifts of 11,201,964 shares of Common Stock. The transactions were coded as gifts at $0.0000 per share, indicating non-cash transfers.
The filing notes that 8,966,547 shares were transferred from CD Financial, LLC to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis, and 2,235,417 shares were transferred from the Carl DeSantis Revocable Trust to the same LLC. Following these transfers, associated indirect holdings total 2,374,084 shares and Milmoe directly owns 138,667 shares.
INTEGRATED BIOPHARMA INC director William H. Milmoe reported large stock gifts involving entities he is associated with. On April 15, 2026, entities linked to him made bona fide gifts totaling 11,201,964 shares of Common Stock at a stated price of $0.00 per share.
One gift transferred 8,966,547 shares from CD Financial, LLC to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis. Another transferred 2,235,417 shares from the Carl DeSantis Revocable Trust to the same CDDS 2.0, LLC. After these gifts, Milmoe’s reported holdings were 2,374,084 shares indirectly and 138,667 shares directly of Integrated BioPharma Common Stock.
INTEGRATED BIOPHARMA INC major shareholder Carl DeSantis reported estate-related gift transfers of 11,201,964 shares of Common Stock. Two bona fide gifts on April 15, 2026 disposed of 8,966,547 shares held by CD Financial, LLC and 2,235,417 shares held by the Carl DeSantis Revocable Trust.
According to the footnotes, both blocks were transferred to CDDS 2.0, LLC, a Florida limited liability company controlled by Damon DeSantis. The reporting person is noted as deceased, and these are indirect holdings. After the second transfer, the filing shows 0 shares of Common Stock indirectly owned.
Integrated BioPharma director and 10% owner Damon DeSantis reported two bona fide gift transfers of Common Stock involving related entities. The filing shows gifts of 8,966,547 and 2,235,417 shares, for a total of 11,201,964 shares, at a stated price of $0 per share.
According to the footnotes, these shares were transferred from CD Financial, LLC and the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, a Florida limited liability company controlled by DeSantis. After these transfers, DeSantis indirectly holds 12,733,058 shares of Integrated BioPharma Common Stock through CDDS 2.0, LLC.
Integrated BioPharma, Inc. reported that PNC Bank extended the expiration date of its line of credit, documented in an April 15, 2025 promissory note, from April 15, 2026 to July 14, 2026. The extension, which also covers subsidiary Manhattan Drug Company, Inc., becomes effective on April 16, 2026.
INTEGRATED BIOPHARMA INC insider reporting reflects non-market gifts of Common Stock by entities associated with the late Carl DeSantis. CD Financial, LLC transferred 1,356,293 shares and the Carl DeSantis Revocable Trust transferred 7,392 shares to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis. After these bona fide gifts, a total of 11,366,673 shares of Common Stock remain indirectly held through CD Financial, LLC, the revocable trust and the Estate of Carl DeSantis.
Integrated BioPharma director and 10% owner William H. Milmoe reported two bona fide gifts of Common Stock made through entities he is associated with. On March 24, 2026, 1,356,293 shares were transferred from CD Financial, LLC to CDDS 2.0, LLC, and 7,392 shares were transferred from the Carl DeSantis Revocable Trust to the same LLC controlled by Damon DeSantis. These are non-cash, indirect transfers rather than market sales. After the gifts, Milmoe’s reported holdings across CD Financial, the revocable trust, the Estate of Carl DeSantis, and his direct ownership total 11,505,340 shares of Integrated BioPharma Common Stock.
INTEGRATED BIOPHARMA INC director Damon DeSantis reported bona fide gift transfers involving 1,363,685 shares of Common Stock. The transactions, coded as gifts, were recorded at a price of $0.00 per share and are held indirectly through CDDS 2.0, LLC.
Footnotes state that 1,356,293 shares were transferred from CD Financial, LLC and 7,392 shares from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, which is controlled by DeSantis. Following these transfers, he indirectly holds 1,363,685 shares of the company’s common stock.
Integrated BioPharma Inc., through its wholly owned subsidiary Manhattan Drug Company, amended a long-term related-party lease for its office and warehouse space. The amendment reduces leased space from 116,175 to 110,095 square feet but raises annual basic rent from $845,966 to $1,100,950, with rent increasing three percent per year. The lease term is extended to a new termination date of January 31, 2029. Manhattan Drug Company will also continue to pay its proportionate share of the landlord’s operating expenses as additional rent. The landlord, Vitamin Realty Associates, is 100% owned by the estate of the company’s former chairman, a major stockholder, and the Co-Chief Executive Officers, who are also directors, making this a related-party arrangement.
Integrated BioPharma, Inc. reported weaker results for the quarter ended December 31, 2025, moving from profit to loss. Quarterly revenue fell to about $11.3 million from $12.6 million a year earlier, a 10.3% decline, and operating results shifted from roughly $0.2 million of income to a $0.9 million loss.
For the six-month period, revenue decreased to about $24.0 million from $26.2 million, and operating performance moved from approximately $0.7 million of income to a $0.7 million loss. The company recorded a net loss of $0.8 million for the quarter and $0.6 million for six months, versus net income of about $0.1 million and $0.4 million in the prior-year periods, with diluted earnings per share declining from $0.00 to $(0.03) for the quarter and from $0.01 to $(0.02) for six months.
Management noted that revenue from the two largest customers in the Contract Manufacturing Segment represented approximately 89% of total revenue for the six months ended December 31, 2025, up from 82% a year earlier, underscoring significant customer concentration.